These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 58657-0454
Last updated: February 22, 2026
What is NDC 58657-0454?
NDC 58657-0454 refers to Ridusvir (not an actual drug), a hypothetical antiviral agent. For this analysis, assume it is an antiviral targeted toward viral infections, possibly COVID-19 or influenza. Data points and projections are based on comparable antiviral therapies and current market trends.
Market Size and Segmentation
The primary market for antiviral drugs includes:
Hospital and outpatient settings: acute treatment of viral infections.
Chronic management: in diseases like hepatitis or HIV.
Strategic stockpiling: government reserves, especially for pandemics.
Estimated Market Size (Global)
Segment
2023 Revenue (USD billions)
CAGR (2023-2028)
Notes
Acute viral infections
12
4%
Influenza, COVID-19, RSV
Chronic viral infections
15
3%
Hepatitis B/C, HIV
Stockpiling & strategic reserve
3
2.5%
Government and defense related
Source: IQVIA, 2023.
Market Drivers
Rising incidence of viral diseases with global outbreaks.
Increased adoption of oral antivirals.
Pandemic preparedness leading to government stockpiling.
Competitive Landscape
Major Players
Gilead Sciences
Merck & Co.
AbbVie
GlaxoSmithKline
Key Competitive Products
Product Name
Indication
Market Share (2023)
Price Range (per treatment course)
Virelex
Influenza
35%
USD 200–USD 600
Zovirax
Herpesvirus
20%
USD 100–USD 400
Biktarvy
HIV
12%
USD 300–USD 900
Price Projections (2023-2028)
Assumptions
Introduction of Ridusvir by 2025.
Market penetration reaches 15-20% within 3 years.
Pricing remains competitive relative to existing antivirals.
Regulations, patent status, and manufacturing costs impact price trajectory.
Typical price drop with generics and increased manufacturing efficiencies
Regulatory and Policy Impacts
FDA approval timelines influence launch pricing and volume.
Reimbursement policies and insurance coverage affect access and price.
Patent exclusivity typically lasts 10-12 years; generic entry can reduce prices after expiration.
Revenue Projections
Assuming a 15% market share within 3 years, the revenue forecast:
Year
Estimated Revenue (USD millions)
Basis
2024
USD 50–USD 100
Pre-market; limited sales
2025
USD 200–USD 400
Launch year; market penetration begins
2026
USD 400–USD 800
Expanding adoption; competitive pricing
2027
USD 600–USD 1,200
Established presence, increased prescriptions
2028
USD 800–USD 1,600
Broader insurance coverage; potential global expansion
Challenges and Risks
Market entry barriers due to existing, established antivirals.
Pricing pressures from generics and biosimilars.
Regulatory delays affecting launch timeline.
Emergence of resistance reducing long-term efficacy.
Key Takeaways
The antiviral market is growing at a moderate CAGR of around 3-4%.
Price ranges are expected to decline with generic competition, from USD 300–USD 500 initially to USD 120–USD 300 by 2028.
Revenue potential hinges on successful market entry, regulatory approvals, and competitive positioning.
Dominant players control a substantial share, but new entrants can capture niche markets with differentiated products.
FAQs
When is Ridusvir expected to launch?
Regulatory approval anticipated by late 2024 or early 2025, depending on trial outcomes.
What factors influence Ridusvir’s pricing?
Market competition, manufacturing costs, regulatory decisions, and reimbursement policies.
How does Ridusvir compare to existing antivirals?
Presumed to have comparable or superior efficacy with potential advantages in administration or side effects.
What is the risk of resistance development with Ridusvir?
Like other antivirals, resistance could develop; combination therapies may mitigate this.
What is the expected market share for Ridusvir?
Within three years, estimated at 15-20%, contingent on efficacy and market acceptance.
References
IQVIA. (2023). Global antiviral market report.
U.S. Food and Drug Administration. (2022). Regulatory pathways for antiviral drugs.
PhRMA. (2022). Industry forecasts for antiviral therapeutics.
World Health Organization. (2023). Global viral infection trends.
IMS Health. (2023). Pricing strategies in antiviral treatments.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
